65.22
Precedente Chiudi:
$63.55
Aprire:
$63.76
Volume 24 ore:
639.59K
Relative Volume:
0.92
Capitalizzazione di mercato:
$1.65B
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-167.22
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
+5.19%
1M Prestazione:
+26.64%
6M Prestazione:
+172.41%
1 anno Prestazione:
+415.94%
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Confronta CDTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CDTX
Cidara Therapeutics Inc
|
65.22 | 1.61B | 56.54M | -30.70M | -31.05M | -0.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-18 | Ripresa | H.C. Wainwright | Buy |
2025-03-12 | Iniziato | Citizens JMP | Mkt Outperform |
2025-01-27 | Ripresa | Cantor Fitzgerald | Overweight |
2024-12-13 | Iniziato | RBC Capital Mkts | Outperform |
2024-11-08 | Iniziato | Guggenheim | Buy |
2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-12-03 | Ripresa | H.C. Wainwright | Buy |
2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
2021-03-04 | Iniziato | Aegis Capital | Buy |
2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
2018-07-26 | Iniziato | Citigroup | Buy |
2017-04-21 | Iniziato | Raymond James | Strong Buy |
2017-04-17 | Reiterato | H.C. Wainwright | Buy |
2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
2017-04-11 | Ripresa | Wedbush | Outperform |
2017-02-22 | Reiterato | H.C. Wainwright | Buy |
2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
2016-12-21 | Ripresa | Leerink Partners | Outperform |
2016-12-19 | Iniziato | H.C. Wainwright | Buy |
2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
2015-05-11 | Iniziato | Jefferies | Buy |
2015-05-11 | Iniziato | Leerink Partners | Outperform |
2015-05-11 | Iniziato | Needham | Buy |
2015-05-11 | Iniziato | Wedbush | Outperform |
2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Cidara Therapeutics: A High-Conviction Biotech Play with Clear Path to FDA Phase 3 and Market Disruption - AInvest
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Fund Update: MORGAN STANLEY added 875,198 shares of CIDARA THERAPEUTICS (CDTX) to their portfolio - Quiver Quantitative
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript - MSN
Cidara (CDTX) Q2 Cash Surges 163% - AOL.com
Cidara Therapeutics Inc. Pullback Analyzed — Is It Time to ExitMarket Entry and Exit Point Tips From Traders - beatles.ru
A Quick Look at Today's Ratings for Cidara Therapeutics(CDTX.US), With a Forecast Between $66 to $74 - 富途牛牛
Cidara Therapeutics 2024 Q2 Earnings Net Loss Widens by 569.5% - AInvest
Cidara Therapeutics price target raised to $74 from $54 at Needham - TipRanks
Guggenheim raises Cidara Therapeutics stock price target to $70 on FDA meeting progress - Investing.com Canada
Cidara Therapeutics Rallies On Promising Flu Drug Progress - Finimize
Cidara Therapeutics Reports Positive Trial Results and Financial Growth - TipRanks
Earnings call transcript: Sidera Therapeutics’ Q2 2025 innovation focus - Investing.com
Cidara Therapeutics: Q2 Earnings Snapshot - Manistee News Advocate
Cidara Therapeutics stock price target raised to $66 at Citizens JMP - Investing.com Australia
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... - Yahoo Finance
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ... By GuruFocus - Investing.com Canada
Cidara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cidara Therapeutics 2024 Q2 Earnings Deepened Losses Amid Strong Clinical Progress - AInvest
Transcript : Cidara Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82) - TipRanks
Cidara Therapeutics Q2 net loss narrows - MarketScreener
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Spero leads infectious disease gains with 252% stock jump - BioWorld MedTech
RBC Capital raises Cidara Therapeutics stock price target to $115 on market potential - Investing.com Canada
Cidara Therapeutics price target raised to $115 from $75 at RBC Capital - TipRanks
Cidara Therapeutics Inc expected to post a loss of $2.00 a shareEarnings Preview - TradingView
Cidara Therapeutics CDTX Q2 2025 Earnings Preview Upside Potential on Analyst Optimism - AInvest
Is Cidara Therapeutics Inc. stock overvalued or undervaluedCapitalize on market momentum for maximum gains - Jammu Links News
Should I hold or sell Cidara Therapeutics Inc. stock in 2025Achieve breakthrough gains with expert advice - Jammu Links News
Cidara Therapeutics Inc. Stock Analysis and ForecastInvest smarter with data-backed insights - Jammu Links News
How strong is Cidara Therapeutics Inc. company’s balance sheetGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Cidara Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
What makes Cidara Therapeutics Inc. stock price move sharplyRecord-breaking capital gains - Jammu Links News
Is Cidara Therapeutics Inc. a good long term investmentInvest with confidence backed by data - Jammu Links News
What are analysts’ price targets for Cidara Therapeutics Inc. in the next 12 monthsDynamic portfolio growth - Jammu Links News
What is the risk reward ratio of investing in Cidara Therapeutics Inc. stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
What is the dividend policy of Cidara Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What are Cidara Therapeutics Inc. company’s key revenue driversAchieve rapid capital gains with smart investing - Jammu Links News
Will Cidara Therapeutics Inc. Bounce From 52 Week LowTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Moving Average Crossover Confirms Uptrend in Cidara Therapeutics Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How Cidara Therapeutics Inc. stock performs during market volatilityHigh Win Rate Trading Opportunities Detected - beatles.ru
Can trapped investors hope for a rebound in Cidara Therapeutics Inc.Real-Time Trade Insights Spark Market Reactions - metal.it
Will Cidara Therapeutics Inc. stock split in the near futureInvestment Strategy With Predictable Gains Outlined - metal.it
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):